Aurobindo Pharma USA, Inc Committed to a Healthier Life

Profile
Aurobindo Pharma USA, Inc
Committed to a Healthier Life
A
urobindo USA is committed to delivering a
broad portfolio of quality, affordable generic
pharmaceuticals to pharmacists and patients.
Since its first US ANDA approval in 2004,
Aurobindo has expanded its portfolio to include more than
125 product families and 450 individual product packages,
representing a wide range of therapeutic categories.
Aurobindo has been recognized as the fastest growing
pharmaceutical company in 2012,* and in early 2013,
thanks to the ongoing support of our customers, became one
of the top 10 pharmaceutical companies, brand or generic,
in terms of total prescriptions dispensed.** Aurobindo
continues to invest in the portfolio and was also recognized
during the first quarter of 2013 with the highest number of
ANDAs approved of all generic manufacturers.***
Being part of a global organization with revenues exceeding $1 billion, combined with extensive capacities and capabilities in active pharmaceutical ingredients, intermediates,
and finished dosage forms, Aurobindo USA is able to lever-
age this highly efficient infrastructure to deliver excellent
value to our customers. As one of the largest suppliers of
API across the globe, combined with quality, manufacturing, and formulation expertise, Aurobindo has created a
vertically integrated process poised to continue expansion
within the US market.
In addition to our global production, Aurobindo operates 2 facilities in central New Jersey, with approximately
300,000 square feet of laboratory, manufacturing, distribution, and administrative space with more than 200 talented
associates. Through our flexibility in balancing highly
efficient global production with in-market capabilities
for packaging and controlled substance development and
manufacture, Aurobindo is diversifying into a wide range
of products and dosage forms.
With a consistent focus on quality, affordability, and customer satisfaction, Aurobindo is well positioned to deliver
consistent growth and value to our customer partners in the
years ahead. ■
*Source: IMS National Prescription Audit, December 2012.
**Source: IMS National Prescription Audit, January – March 2013.
***Source: Thomson Reuters, Movers and Shakers, May 2013.
Robert Cunard, CEO
James Grauso, SVP Commercial Operations
12
n
07.13 | Pharmacy Timeswww.PharmacyTimes.com
Profile
Aurobindo Pharma USA, Inc
Committed to a Healthier Life
Aurobindo USA’s Significant New Product Introductions During the Past
Year Include:
• Abacavir Sulfate Tablets
• Montelukast Sodium Tablets
• Clopidogrel Bisulfate Tablets
• Montelukast Sodium Chewable Tablets
• Hydrocodone Bitartrate / Acetaminophen Tablets
• Oxycodone Hydrochloride Tablets
• Lamivudine / Zidovudine Tablets
• Pioglitazone / Metformin Tablets
• Modafinil Tablets
• Valsartan / Hydrochlorothiazide Tablets
In early 2013, Aurobindo reintroduced the Cephalexin family of
products:
• Cefdinir Capsules and Oral Suspension
•C
efpodoxime Proxetil Tablets and Oral
Suspension
• Cefuroxime Axetil Tablets
• Cephalexin Capsules
Aurobindo USA’s headquarters in Dayton, New Jersey.
For more information, visit www.aurobindousa.com
or call 866-850-2876 or 732-839-9400.
www.PharmacyTimes.com
Pharmacy Times | 07.13
n
13